During a median follow-up of 2.5 years, 1.6 per cent of patients who received
atorvastatin and 2.4 per cent of patients receiving placebo experienced cardiovascular death, heart attack, stroke, transient ischemic attack, or any arterial revascularisation.
The first-order derivative overlaid spectra of
atorvastatin calcium and fenofibrate denoted that there was no zero crossing point for
atorvastatin calcium for quantification of fenofibrate (Figure 2).
Yamakawa et al reported a significant increase in glycated hemoglobin (HbA1c) in patients with diabetes receiving
Atorvastatin treatment for 3 months, whereas only a minimal change in HbA1c in patients receiving Pitavastatin14.
Cell viability and cytotoxic effects caused by
atorvastatin were determined by a WST-1 assay.
Different statins have varied propensities for causing self-limited myopathy, with
atorvastatin and simvastatin associated with higher rates of myopathy than rosuvastatin; however, there is no established association between specific statins and the occurrence of SINAM [7, 8].
PubMed database was used to search for publications of interest using as keywords "
atorvastatin AND diabetes." Eligible studies were primary studies of every design (observational studies, cross-sectional, cohort, case studies, case series, clinical trials, etc.) published in English until 30/ 04/2015 (date of last search).
Conclusion:
Atorvastatin used as an adjuvant therapy with currently existing standard therapy (topical betamethasone) in patients having mild to moderate plaque type psoriasis reduces disease severity and cardiovascular risks.
Oral administration of
atorvastatin (10 mg) led to decline in CFFF from the baseline score taken before intake of test drug.
Analysis of the proliferation assays shows that both
atorvastatin solution and atorvastatin-medicated dentifrice reduced the percentage of CD4+ T cell proliferation compared with control and dentifrice without
atorvastatin.
Our case highlights a serious drug induced myotoxicity from high dose
atorvastatin, two and a half months after instituting ticagrelor and continuing with amlodipine.
At the same time, the patient remained on her therapeutic regimen, which included
atorvastatin 20 mg once daily.